GET DAILY SIGNALSZymeworks (ZYME) Q3 2026 Earnings: Milestone Payment Drives Record Results
Key Takeaways
- Total revenue surged to $256.5 million in the third quarter of 2026, up from $27.6 million in the same period a year earlier.
- Net income reached $173.7 million, a sharp turnaround from a net loss of $19.6 million in Q3 2025.
- The jump was driven largely by a $250.0 million milestone payment from partner Jazz Pharmaceuticals following U.S. approval of Ziihera.
- Adjusted earnings of $2.28 per share came in below the Zacks Consensus Estimate of $2.40, while revenue beat expectations.
- Zymeworks raised its full-year 2026 guidance, lifting both revenue and adjusted EBITDA targets.
- The quarter also reflected early integration costs from the Theravance Biopharma acquisition, which closed in September.
Earnings Context and Why It Matters
Zymeworks' third-quarter 2026 results arrive at a pivotal moment for the biotech's strategy of pairing a royalty-generating asset portfolio with an internal drug development engine. The period captures both a landmark regulatory event and a major corporate transaction. In August 2026, partner Jazz Pharmaceuticals secured U.S. Food and Drug Administration approval for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, triggering a substantial milestone. Weeks later, Zymeworks completed its acquisition of Theravance Biopharma. These events make the quarter's headline figures unusual, as one-time milestones and acquisition costs distort comparisons with prior periods. For investors, the report is less about routine operating trends and more about how these strategic moves reshape revenue, expenses, and cash flow visibility. I also checked this using Tickeron’s AI Screener to see how ZYME compares to peers in the space.
Reported Results
Zymeworks reported total revenue of $256.5 million for the quarter ended September 30, 2026, compared with $27.6 million a year earlier. The increase primarily reflected the $250.0 million milestone earned from Jazz following U.S. approval of Ziihera for first-line HER2-positive GEA, partly offset by the absence of a $25.0 million development milestone from Johnson & Johnson Innovative Medicine recognized in Q3 2025. Theravance Biopharma contributed roughly $1.5 million of revenue during its seven days of ownership.
The company posted net income of $173.7 million, versus a net loss of $19.6 million in the prior-year quarter. Research and development expenses were $36.1 million (up slightly from $35.6 million), while selling, general, and administrative expenses rose to $42.7 million from $14.1 million, driven by acquisition-related severance, transaction fees, and higher stock-based compensation. Other income swung to a net expense of $4.4 million, reflecting interest on royalty-backed financing with Royalty Pharma.
On an adjusted basis, earnings of $2.28 per share came in below the consensus estimate of $2.40, while revenue of $256.46 million surpassed expectations. Zymeworks also raised 2026 guidance to $337 million–$351 million in total revenue and $176 million–$190 million in adjusted EBITDA.
Market Reaction and Investor Sentiment
Investor attention around this report centered on two competing forces: an exceptionally strong headline quarter and an adjusted EPS figure that fell short of elevated consensus expectations. The $250 million Ziihera milestone pushed reported results well beyond any prior quarter, but the adjusted per-share miss reflects the difficulty analysts had modeling a period distorted by one-time items and acquisition costs. Sentiment also incorporates the company's raised 2026 guidance and its recently announced global collaboration with Roche on ZW209, which added an upfront payment, milestone potential, and royalty economics. Share repurchases, with roughly $279.8 million deployed cumulatively since August 2024, signal management confidence in the balance sheet. Zymeworks does not host a conference call for this quarter, leaving the press release as the primary driver of interpretation.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on execution across Zymeworks' newly expanded portfolio. The integration of Theravance Biopharma adds commercial and near-commercial assets, including YUPELRI collaboration revenue, which grew modestly year over year. Watch whether acquisition-related costs moderate in coming quarters and whether the combined business can sustain operational momentum alongside higher SG&A.
A second area to monitor is the ZW209 collaboration with Roche. Pending Hart-Scott-Rodino clearance, this agreement carries an upfront payment and significant milestone potential, offering another source of non-dilutive funding if development advances. Progress here could shape how investors value the internal pipeline beyond the existing Ziihera franchise.
Finally, the revised full-year guidance provides a clearer near-term benchmark. With total revenue now guided to $337 million–$351 million and adjusted EBITDA to $176 million–$190 million, investors will assess whether milestone timing, integration costs, and royalty-backed interest expense keep results within these ranges. Clinical and regulatory catalysts across the company's programs remain key swing factors in the quarters ahead.
Using Tickeron’s AI Screener for Biotech Analysis
One tool I frequently turn to when evaluating names like ZYME is Tickeron’s AI Screener. It lets me quickly filter biotechnology stocks by fundamentals, technical patterns, and AI-driven signals, helping spot how peers stack up on metrics such as revenue growth and margin trends. This kind of structured scan adds useful context without replacing deep fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZYME in upward trend: price rose above 50-day moving average on October 20, 2026
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZYME as a result. In 71 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 41 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 63 cases where ZYME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.498). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company for cancer & autoimmune treatment
Industry Biotechnology
Advertisement